Overview

Corporate Profile

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Our product development programs target specific subsets of cancer, and we seek to simultaneously develop, with partners, companion diagnostics that direct our product candidates to the patients most likely to benefit from their use. We believe this approach to personalized medicMore >>

Stock Chart
Stock chart for: 03NA000000CLVS
Stock Quote
CLVS (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$36.05
Change (%) Stock is Up 1.41 (4.07%)
Intraday High$36.15
Intraday Low$33.88
Volume2,246,205
Data as of 09/30/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle  
09/28/16Clovis Oncology Announces Rucaparib Data Presentations at ESMO 2016 Congress
Data for rucaparib in the treatment of advanced ovarian cancer to be highlighted in oral presentation U.S. Food and Drug Administration (FDA) accepted accelerated approval application for review and granted priority review status Prescription Drug User Fee Act (PDUFA) date is February 23, 2017 European Marketing Authorization Application (MAA) planned in Q4 2016 BOULDER, Colo.... 
Printer Friendly Version 
08/23/16FDA Accepts Clovis Oncology’s New Drug Application for Rucaparib for Priority Review for the Treatment of Advanced Mutant BRCA Ovarian Cancer
Seeking approval for mutant BRCA patients treated with two or more prior therapies FDA Grants Priority Review Status Assigns PDUFA Date of February 23, 2017 BOULDER, Colo.--(BUSINESS WIRE)--Aug. 23, 2016-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the U.S. Food and Drug Administration (FDA) has accepted Clovis’ New Drug Application (NDA) for accelerated approval of rucaparib and gra... 
Printer Friendly VersionDownload PDF
08/08/16Clovis Oncology Announces Q2 2016 Operating Results and Corporate Update
Rucaparib NDA submission completed in late June for treatment of patients with advanced ovarian cancer with deleterious BRCA mutated tumors FDA decision on filing and determination of PDUFA date is anticipated in late August Rucaparib MAA submission on track for Q4 2016 Rucaparib NDA dataset accepted for an oral presentation at ESMO 2016 Congress in October Clov... 
Printer Friendly VersionDownload PDF
Upcoming EventsMore >>
There are currently no events scheduled.
Receive Email AlertsEmail Alert Icon
Sign up to receive email alerts whenever Clovis Oncology, Inc. posts new information to the site. Just enter your email address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.